TOKYO -- Fujifilm Holdings, developer of anti-flu treatment Avigan, will invest about 100 billion yen ($928 million) to ramp up production of biopharmaceuticals at its plant in Denmark, the company announced Tuesday, in response to increasing demand for medicines as therapeutic agents.
Pharmaceuticals
Fujifilm invests $930m in Denmark to double bio-drug output
Japanese developer of Avigan expanding facility for production and packaging
Fujifilm is planning a major expansion of biopharmaceutical production at its Denmark factory.
Read Next
Latest on Pharmaceuticals
